{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T09:54:55Z","timestamp":1772358895965,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1047673"],"award-info":[{"award-number":["1047673"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ijrobp.2022.08.006","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T12:08:36Z","timestamp":1660133316000},"page":"174-188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Patient- and Clinician-Reported Outcomes in Human Papillomavirus-Associated Tonsillar Carcinoma Treated With Unilateral and Bilateral Intensity Modulated Radiation Therapy\u2013A Substudy From TROG 12.01"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4268-3079","authenticated-orcid":false,"given":"Lachlan","family":"McDowell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Rischin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeleine","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizbeth","family":"Kenny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro","family":"Porceddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Wratten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Macann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Bressel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsien","family":"Fua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"June","family":"Corry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2022.08.006_bib0001","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1200\/JCO.19.01007","article-title":"Phase II trial of de-intensified chemoradiotherapy for human papillomavirus-associated oropharyngeal squamous cell carcinoma","volume":"37","author":"Chera","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0002","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ijrobp.2015.08.033","article-title":"Phase 2 trial of de-intensified chemoradiation therapy for favorable-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma","volume":"93","author":"Chera","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0003","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1200\/JCO.21.01752","article-title":"Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: An ECOG-ACRIN cancer research group trial (E3311)","volume":"40","author":"Ferris","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0004","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): A randomised, multicentre, non-inferiority trial","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0005","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.2016.68.3300","article-title":"E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx\u2013ECOG-ACRIN Cancer Research Group","volume":"35","author":"Marur","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0006","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","article-title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): An open-label randomised controlled phase 3 trial","volume":"393","author":"Mehanna","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0007","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ijrobp.2021.04.015","article-title":"Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk HPV-associated oropharyngeal cancer (TROG 12.01) \u2013 A Trans-Tasman Radiation Oncology Group Study","volume":"111","author":"Rischin","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0008","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.20.03128","article-title":"Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002)","volume":"39","author":"Yom","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0009","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ctrv.2017.07.004","article-title":"Contralateral regional recurrence after elective unilateral neck irradiation in oropharyngeal carcinoma: A literature-based critical review","volume":"59","author":"Al-Mamgani","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0010","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.prro.2017.02.002","article-title":"Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO evidence-based clinical practice guideline","volume":"7","author":"Sher","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0011","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/hed.26492","article-title":"Ipsilateral radiation for squamous cell carcinoma of the tonsil: American Radium Society appropriate use criteria executive summary","volume":"43","author":"Tsai","year":"2021","journal-title":"Head & Neck"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.105165","article-title":"Comparing unilateral vs. bilateral neck management in lateralized oropharyngeal cancer between surgical and radiation oncologists: An international practice pattern survey","volume":"114","author":"de Almeida","year":"2021","journal-title":"Oral Oncology"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2021.105248","volume":"119","author":"McDowell","year":"2021","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0014","series-title":"AJCC Cancer Staging Manual","article-title":"American Joint Committee on Cancer","author":"Edge","year":"2010"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0015","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.radonc.2015.07.041","article-title":"CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines","volume":"117","author":"Brouwer","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0016","unstructured":"Cleeland CS. The M. D. Anderson Symptom Assessment Inventory (MDASI) Users Guide 2010. Available at: https:\/\/www.mdanderson.org\/documents\/Departments-and-Divisions\/Symptom-Research\/MDASI_userguide.pdf. Accessed March 28, 2022."},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0017","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/hed.20602","article-title":"Measuring head and neck cancer symptom burden: The development and validation of the M. D. Anderson symptom inventory, head and neck module","volume":"29","author":"Rosenthal","year":"2007","journal-title":"Head & Neck"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0018","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2294::AID-CNCR17>3.0.CO;2-S","article-title":"The Performance Status Scale for Head and Neck Cancer Patients and the Functional Assessment of Cancer Therapy-Head and Neck Scale. A study of utility and validity","volume":"77","author":"List","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0019","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hed.23561","article-title":"Outcomes toolbox for head and neck cancer research","volume":"37","author":"Ringash","year":"2015","journal-title":"Head & Neck"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0020","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1023\/B:QURE.0000021703.47079.46","article-title":"Interpreting differences in quality of life: The FACT-H&N in laryngeal cancer patients","volume":"13","author":"Ringash","year":"2004","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0021","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0022","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/pon.1952","article-title":"The HADS and the DT for screening psychosocial distress of cancer patients in Taiwan","volume":"20","author":"Wang","year":"2011","journal-title":"Psychooncology"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0023","first-page":"1899","article-title":"Accuracy of the Hospital Anxiety and Depression Scale as a screening tool in cancer patients: A systematic review and meta-analysis","volume":"19","author":"Vodermaier","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0024","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2011.41.4375","article-title":"Change in working time in a population-based cohort of patients with breast cancer","volume":"30","author":"H\u00f8yer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0025","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/1097-0142(19900801)66:3<564::AID-CNCR2820660326>3.0.CO;2-D","article-title":"A performance status scale for head and neck cancer patients","volume":"66","author":"List","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0026","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03: National Institutes of Health, National Cancer Institute. Available at: http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed September 20, 2022."},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0027","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.radonc.2007.06.005","article-title":"Morbidity after ipsilateral radiotherapy for oropharyngeal cancer","volume":"85","author":"Jensen","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0028","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.radonc.2012.12.006","article-title":"Unilateral neck irradiation for well-lateralized oropharyngeal cancer","volume":"106","author":"Al-Mamgani","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0029","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.oraloncology.2015.03.013","article-title":"Freedom from local and regional failure of contralateral neck with ipsilateral neck radiotherapy for node-positive tonsil cancer: Updated results of an institutional clinical management approach","volume":"51","author":"Dan","year":"2015","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0030","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ijrobp.2017.01.018","article-title":"Re-evaluation of ipsilateral radiation for T1-T2N0-N2b tonsil carcinoma at the Princess Margaret Hospital in the human papillomavirus era, 25 years later","volume":"98","author":"Huang","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0031","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/hed.23297","article-title":"Tonsillar cancer: the Peter MacCallum experience with unilateral and bilateral irradiation","volume":"36","author":"Liu","year":"2014","journal-title":"Head & Neck"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0032","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1001\/jamaoto.2016.0656","article-title":"Comparison of patient- and practitioner-reported toxic effects associated with chemoradiotherapy for head and neck cancer","volume":"142","author":"Falchook","year":"2016","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0033","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1002\/cncr.30931","article-title":"Comparison of unilateral versus bilateral intensity-modulated radiotherapy for surgically treated squamous cell carcinoma of the palatine tonsil","volume":"123","author":"Chin","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0034","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.ijrobp.2018.10.033","article-title":"Quality of life for patients with favorable-risk HPV-associated oropharyngeal cancer after de-intensified chemoradiotherapy","volume":"103","author":"Pearlstein","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0035","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0167-8140(99)00051-1","article-title":"Cancer of the tonsil: The results of ipsilateral radiation treatment","volume":"51","author":"Jackson","year":"1999","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0036","first-page":"85","article-title":"Patient-reported quality of life and toxicity in unilateral and bilateral radiotherapy for early-stage human papillomavirus associated tonsillar carcinoma","volume":"21","author":"McDowell","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0037","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/hed.27031","article-title":"Association between radiation dose to organs at risk and acute patient reported outcome during radiation treatment for head and neck cancers","volume":"44","author":"Arbab","year":"2022","journal-title":"Head & Neck"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0038","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.radonc.2015.09.007","article-title":"Favorable patient reported outcomes following IMRT for early carcinomas of the tonsillar fossa: Results from a symptom assessment study","volume":"117","author":"Gunn","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0039","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ijrobp.2006.06.013","article-title":"Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: Initial report on a randomized controlled clinical trial","volume":"66","author":"Pow","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0040","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1470-2045(10)70290-4","article-title":"Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): A phase 3 multicentre randomised controlled trial","volume":"12","author":"Nutting","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0041","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ijrobp.2016.03.017","article-title":"Effect of p16 status on the quality-of-life experience during chemoradiation for locally advanced oropharyngeal cancer: A substudy of randomized trial Trans-Tasman Radiation Oncology Group (TROG) 02.02 (HeadSTART)","volume":"97","author":"Ringash","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0042","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ejca.2016.11.008","article-title":"Quality of life and swallowing with standard chemoradiotherapy versus accelerated radiotherapy and panitumumab in locoregionally advanced carcinoma of the head and neck: A phase III randomised trial from the Canadian Cancer Trials Group (HN.6)","volume":"72","author":"Ringash","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2022.08.006_bib0043","unstructured":"ClinicalTrials.gov. Study of Lymphatic Drainage Mapping in Oropharyngeal Cancers. Available at:https:\/\/ClinicalTrials.gov\/show\/NCT05055206. Accessed May 23, 2022."}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301622030899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301622030899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T10:03:28Z","timestamp":1759745008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301622030899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0360301622030899"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2022.08.006","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient- and Clinician-Reported Outcomes in Human Papillomavirus-Associated Tonsillar Carcinoma Treated With Unilateral and Bilateral Intensity Modulated Radiation Therapy\u2013A Substudy From TROG 12.01","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2022.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}